Llewelyn
Andrew Humphrey Llewelyn, Lyme Regis GB
Patent application number | Description | Published |
---|---|---|
20100092962 | Method of Detecting Colorectal Cancer - A method for predicting the presence of colorectal cancer based on the concentration of DNA in a sample of exfoliated cells collected directly from the surface of the rectal mucosa of a subject. The method consists of quantifying the concentration of DNA in a lysate containing exfoliated cells and correlating the concentration with a range within a statistical model which indicated the likelihood of the presence of colorectal cancer as well as the likely location of the cancer. | 04-15-2010 |
Jennifer Llewelyn, Wilmington, DE US
Patent application number | Description | Published |
---|---|---|
20080287418 | Extended Release Compositions and Methods for Their Manufacture - Extended release formulations of quetiapine and its pharmaceutically salts, and methods for manufacture of the formulations, may include the use of polymers selected for their physical and chemical characteristics. The formulations may include polymers selected to cause solid dosage forms of the formulations to conform to preselected quetiapine release criteria. The formulations may include non-polymer materials that may affect quetiapine release. | 11-20-2008 |
20110319383 | Extended Release Formulations Comprising Quetiapine and Methods for Their Manufacture - The present invention relates to extended release formulations of quetiapine and its pharmaceutically acceptable salts. The formulations comprise polymers, preferably hydroxypropyl methylcellulose of different viscosities, selected to cause the formulations to conform to preselected quetiapine release profiles. A process for the manufacture of said formulations is also disclosed. | 12-29-2011 |
Martin John Llewelyn, Brighton GB
Patent application number | Description | Published |
---|---|---|
20140120174 | METHODS OF PROGNOSIS AND DIAGNOSIS OF SEPSIS - Provided are methods of diagnosing sepsis in a patient by detecting the presence and/or amount of at least two biomarkers of sepsis or severe sepsis/septic shock in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having sepsis or severe sepsis/septic shock or suspected of having sepsis or severe sepsis/septic shock, or to accurately diagnose a patient having, or suspected of having sepsis or severe sepsis/septic shock. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for a sepsis therapy. | 05-01-2014 |